tiprankstipranks
Sino Biopharmaceutical Ltd (SBMFF)
OTHER OTC:SBMFF
US Market
SBMFF
Sino Biopharmaceutical
RESEARCH TOOLSreports

Sino Biopharmaceutical (SBMFF) Ratios

44 Followers

Sino Biopharmaceutical Ratios

SBMFF's free cash flow for Q2 2026 was ¥0.83. For the 2026 fiscal year, SBMFF's free cash flow was decreased by ¥ and operating cash flow was ¥0.34. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 1.63 1.37 1.26 1.05 1.29
Quick Ratio
 1.56 1.28 1.14 0.96 1.17
Cash Ratio
 0.55 0.29 0.49 0.42 0.43
Solvency Ratio
 0.09 0.10 0.20 0.13 0.14
Operating Cash Flow Ratio
 0.23 0.37 0.34 0.27 0.31
Short-Term Operating Cash Flow Coverage
 0.71 1.10 0.86 0.54 0.65
Net Current Asset Value
¥ 7.08B¥ 1.16B¥ 2.05B¥ -1.63B¥ -185.83M
Leverage Ratios
Debt-to-Assets Ratio
 0.21 0.21 0.15 0.20 0.22
Debt-to-Equity Ratio
 0.53 0.52 0.31 0.41 0.47
Debt-to-Capital Ratio
 0.35 0.34 0.23 0.29 0.32
Long-Term Debt-to-Capital Ratio
 0.21 0.20 0.06 0.03 0.12
Financial Leverage Ratio
 2.55 2.48 2.05 2.09 2.15
Debt Service Coverage Ratio
 0.99 0.65 0.70 0.53 0.59
Interest Coverage Ratio
 0.00 25.65 20.79 11.68 13.01
Debt to Market Cap
 0.21 0.16 0.19 0.17 0.18
Interest Debt Per Share
 0.95 0.91 0.58 0.56 0.77
Net Debt to EBITDA
 0.22 1.20 0.04 0.45 0.80
Profitability Margins
Gross Profit Margin
82.43%82.07%81.51%80.95%82.76%
EBIT Margin
28.17%19.76%17.91%22.54%21.69%
EBITDA Margin
30.89%22.79%21.16%26.64%25.71%
Operating Profit Margin
29.76%21.84%21.26%22.08%21.46%
Pretax Profit Margin
24.67%21.81%18.28%20.65%20.04%
Net Profit Margin
7.09%7.36%12.12%8.90%9.77%
Continuous Operations Profit Margin
19.20%16.69%16.57%17.61%17.36%
Net Income Per EBT
28.73%33.75%66.32%43.10%48.78%
EBT Per EBIT
82.92%99.85%86.01%93.50%93.36%
Return on Assets (ROA)
2.87%3.08%5.35%3.67%3.97%
Return on Equity (ROE)
7.56%7.64%10.95%7.65%8.55%
Return on Capital Employed (ROCE)
17.85%13.68%13.38%14.11%12.72%
Return on Invested Capital (ROIC)
12.03%8.98%10.39%9.45%9.02%
Return on Tangible Assets
3.18%3.40%5.61%3.72%4.09%
Earnings Yield
2.83%2.34%6.71%3.28%3.38%
Efficiency Ratios
Receivables Turnover
 3.16 4.79 5.76 5.70 5.60
Payables Turnover
 2.73 3.81 3.56 3.74 3.08
Inventory Turnover
 3.01 2.53 2.25 2.50 2.49
Fixed Asset Turnover
 3.35 3.11 2.81 2.64 2.81
Asset Turnover
 0.41 0.42 0.44 0.41 0.41
Working Capital Turnover Ratio
 1.98 4.42 9.12 7.50 3.73
Cash Conversion Cycle
 103.43 124.75 123.28 112.22 93.15
Days of Sales Outstanding
 115.62 76.16 63.38 64.03 65.12
Days of Inventory Outstanding
 121.29 144.37 162.32 145.82 146.67
Days of Payables Outstanding
 133.47 95.79 102.43 97.63 118.64
Operating Cycle
 236.91 220.54 225.71 209.85 211.79
Cash Flow Ratios
Operating Cash Flow Per Share
 0.34 0.51 0.38 0.26 0.34
Free Cash Flow Per Share
 0.29 0.42 0.30 0.19 0.24
CapEx Per Share
 0.05 0.09 0.08 0.07 0.09
Free Cash Flow to Operating Cash Flow
 0.84 0.82 0.79 0.72 0.73
Dividend Paid and CapEx Coverage Ratio
 2.48 2.90 2.04 2.60 2.11
Capital Expenditure Coverage Ratio
 6.33 5.46 4.74 3.56 3.67
Operating Cash Flow Coverage Ratio
 0.36 0.58 0.68 0.48 0.45
Operating Cash Flow to Sales Ratio
 0.18 0.29 0.23 0.23 0.24
Free Cash Flow Yield
6.19%7.57%10.01%6.14%6.07%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 35.20 42.70 14.90 30.45 29.54
Price-to-Sales (P/S) Ratio
 2.47 3.15 1.81 2.71 2.89
Price-to-Book (P/B) Ratio
 2.59 3.27 1.63 2.33 2.53
Price-to-Free Cash Flow (P/FCF) Ratio
 16.15 13.21 9.99 16.28 16.48
Price-to-Operating Cash Flow Ratio
 13.78 10.79 7.88 11.71 11.99
Price-to-Earnings Growth (PEG) Ratio
 -0.86 -1.22 0.10 -1.08 -0.34
Price-to-Fair Value
 2.59 3.27 1.63 2.33 2.53
Enterprise Value Multiple
 8.23 15.01 8.57 10.62 12.03
Enterprise Value
 85.68B 108.90B 52.37B 74.13B 80.47B
EV to EBITDA
 8.23 15.01 8.57 10.62 12.03
EV to Sales
 2.54 3.42 1.81 2.83 3.09
EV to Free Cash Flow
 16.59 14.35 10.03 17.00 17.65
EV to Operating Cash Flow
 13.97 11.72 7.92 12.22 12.84
Tangible Book Value Per Share
 2.11 1.98 2.30 1.59 1.93
Shareholders’ Equity Per Share
 1.80 1.70 1.85 1.30 1.60
Tax and Other Ratios
Effective Tax Rate
 0.22 0.23 0.09 0.15 0.13
Revenue Per Share
 1.87 1.76 1.67 1.12 1.40
Net Income Per Share
 0.13 0.13 0.20 0.10 0.14
Tax Burden
 0.29 0.34 0.66 0.43 0.49
Interest Burden
 0.88 1.10 1.02 0.92 0.92
Research & Development to Revenue
 0.18 0.19 0.18 0.17 0.17
SG&A to Revenue
 0.35 0.41 0.42 0.07 0.08
Stock-Based Compensation to Revenue
 <0.01 <0.01 <0.01 <0.01 <0.01
Income Quality
 2.57 1.34 0.95 1.02 1.08
Currency in CNY